Takeda Pharmaceutical Company Limited Stock News

One of these high-yield pharma stocks stands out as a better buy right now.

High-yield dividend stocks can be great additions to a long-term-oriented portfolio. Takeda Pharmaceutical and AT&T screen as two of the most attractive buys in the high-yield space right now.

Christophe Weber, CEO of Takeda, says there are some setbacks in research and development, but most of those drugs should fuel the company's growth in the future.

Takeda Pharmaceutical Co said on Tuesday it was voluntarily withdrawing its application for its dengue vaccine candidate, following discussions with the U.S. health regulator.

Takeda Pharmaceutical's stock has appreciated 10% since December, with economic and fundamental catalysts supporting a buy rating. TAK has shown strong growth in revenue and operating capital as well

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2022 Results Conference Call May 11, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Global Head of IR & Global Finance Christophe Webe

Sales of Takhzyro amounted to 44.1 billion Japanese yen in the 3rd quarter of 2022, an increase of 42.7% from the previous year. Takeda Pharmaceutical's revenue was $8,354 million in Q3 2022, showing

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

It's not often you find one stock with sustained price growth and solid dividend yield, but three foreign stocks, Takeda Pharmaceutical Co., Ltd. (NYSE: TAK), United Microelectronics Corp. (NYSE: UMC)

Interest rates may be headed higher and regional banks may be in trouble but that hasn't stopped just a few stocks from hitting new highs.

Takeda's late-stage pipeline is impressive with many candidates boasting very strong fundamentals. Technically though, shares are now coming up against significant overhead resistance.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q3 2023 Earnings Conference Call February 2, 2023 5:30 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - P

When it comes to dividend stocks, the consensus is that the higher the yield, the better. High dividend yields can often be an indication that something is wrong.

Takeda Pharmaceutical Co. Ltd. TAK, +0.43% 4502, +0.65% said Monday that it will acquire Hutchmed's HCM, +1.46% 13, +1.10% experimental cancer treatment outside mainland China, Hong Kong and Macau, wi